Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Klaus, Linz"'
Autor:
Stefanie Frosch, Frank Porreca, Wolfgang P. Schröder, Klaus Schiene, Jennifer Y. Xie, Thomas Christoph, Klaus Linz, Thomas M. Tzschentke
Publikováno v:
Behavioural Pharmacology. 30:320-326
The aim of this study was to investigate the efficacy of cebranopadol in two rodent models of visceral pain. Cebranopadol is a first-in-class analgesic with agonist activity at the nociceptin/orphanin FQ opioid peptide receptor and classical µ-, δ-
Publikováno v:
Addiction Biology. 23:1010-1019
Cebranopadol is a novel potent analgesic agonist at the nociceptin/orphanin FQ peptide (NOP) and classical opioid receptors. As NOP receptor activation has been shown to reduce side effects related to the activation of μ-opioid peptide (MOP) recepto
Publikováno v:
Anesthesiology. 126:708-715
Background Cebranopadol is a first-in-class analgesic with agonist activity at classic opioid peptide receptors and the nociceptin/orphanin FQ peptide receptor. The authors compared the antinociceptive and respiratory depressant effects of cebranopad
Publikováno v:
Handbook of experimental pharmacology. 254
Cebranopadol is a novel first-in-class analgesic with highly potent agonistic activity at nociceptin/orphanin FQ peptide (NOP) and opioid receptors. It is highly potent and efficacious across a broad range of preclinical pain models. Its side effect
Publikováno v:
Handbook of Experimental Pharmacology ISBN: 9783030201852
Cebranopadol is a novel first-in-class analgesic with highly potent agonistic activity at nociceptin/orphanin FQ peptide (NOP) and opioid receptors. It is highly potent and efficacious across a broad range of preclinical pain models. Its side effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::210d3cf5d126c011ff80b0423902e498
https://doi.org/10.1007/164_2019_206
https://doi.org/10.1007/164_2019_206
Publikováno v:
Addiction biology. 23(5)
Cebranopadol is a novel potent analgesic agonist at the nociceptin/orphanin FQ peptide (NOP) and classical opioid receptors. As NOP receptor activation has been shown to reduce side effects related to the activation of μ-opioid peptide (MOP) recepto
Autor:
Klaus Linz, Olaf Will, André Welbers, Virginia Marossek, Rolf Terlinden, Klaus Hansen, Bert Nolte, Irena Loryan, Margareta Hammarlund-Udenaes, Paul Ratcliffe, Achim Kless, Anita Wegert, Derek Saunders, Edmund Hoppe, Felix Held
Drug induced phospholipidosis (PLD) may be observed in the preclinical phase of drug development and pose strategic questions. As lysosomes have a central role in pathogenesis of PLD, assessment of lysosomal concentrations is important for understand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::477e220a5faacb4b5061bcd395774bb2
https://publica.fraunhofer.de/handle/publica/253775
https://publica.fraunhofer.de/handle/publica/253775
Autor:
Sven Frormann, B.Y. Kögel, Bernd Sundermann, Klaus Linz, Achim Kless, Helmut Sonnenschein, Wolfgang P. Schröder, Stefan Schunk, Werner Englberger, Derek Saunders, Hans Schick, Tieno Germann, Saskia Zemolka, Thomas Christoph, Claudia Hinze, Stefan Oberbörsch, Stephanie Harlfinger
Publikováno v:
ACS Medicinal Chemistry Letters. 5:857-862
In a previous communication, our efforts leading from 1 to the identification of spiro[cyclohexane-dihydropyrano[3,4-b]indole]-amine 2a as analgesic NOP and opioid receptor agonist were disclosed and their favorable in vitro and in vivo pharmacologic
Autor:
Tieno Germann, Bernd Sundermann, Sven Frormann, Helmut Sonnenschein, Hans Schick, Werner Englberger, B.Y. Kögel, Derek Saunders, Achim Kless, Klaus Linz, Stefan Oberbörsch, Stephanie Harlfinger, Saskia Zemolka, Thomas Christoph, Claudia Hinze, Wolfgang P. Schröder, Stefan Schunk
Publikováno v:
ACS Medicinal Chemistry Letters. 5:851-856
We report the discovery of spiro[cyclohexane-pyrano[3,4-b]indole]-amines, as functional nociceptin/orphanin FQ peptide (NOP) and opioid receptor agonists with strong efficacy in preclinical models of acute and neuropathic pain. Utilizing 4-(dimethyla
Autor:
Thomas M. Tzschentke, Michael Gautrois, Wolfgang P. Schröder, Stefan Schunk, Werner Englberger, Horst Beier, Thomas Christoph, Klaus Schiene, Jean De Vry, Thomas Koch, Babette Kögel, Ulrich Jahnel, Klaus Linz, Stefanie Frosch
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 349:535-548
Cebranopadol (trans-6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenyl-spiro[cyclohexane-1,1'(3'H)-pyrano[3,4-b]indol]-4-amine) is a novel analgesic nociceptin/orphanin FQ peptide (NOP) and opioid receptor agonist [Ki (nM)/EC50 (nM)/relative efficacy (%):